Feb 20, 2020 4:00pm EST Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
Feb 07, 2020 4:05pm EST Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
Jan 24, 2020 4:30pm EST Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Jan 22, 2020 8:48am EST Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Jan 21, 2020 4:08pm EST Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Jan 14, 2020 2:07am EST Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Jan 13, 2020 8:30am EST Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
Jan 13, 2020 2:00am EST Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
Dec 03, 2019 8:30am EST Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
